LY6E impairs coronavirus fusion and confers immune control of viral disease
Zoonotic coronaviruses (CoVs) are substantial threats to global health, as exemplified by the emergence of two severe acute respiratory syndrome CoVs (SARS-CoV and SARS-CoV-2) and Middle East respiratory syndrome CoV (MERS-CoV) within two decades 1 – 3 . Host immune responses to CoVs are complex and...
Saved in:
Published in | Nature microbiology Vol. 5; no. 11; pp. 1330 - 1339 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
London
Nature Publishing Group UK
01.11.2020
Nature Publishing Group |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Zoonotic coronaviruses (CoVs) are substantial threats to global health, as exemplified by the emergence of two severe acute respiratory syndrome CoVs (SARS-CoV and SARS-CoV-2) and Middle East respiratory syndrome CoV (MERS-CoV) within two decades
1
–
3
. Host immune responses to CoVs are complex and regulated in part through antiviral interferons. However, interferon-stimulated gene products that inhibit CoVs are not well characterized
4
. Here, we show that lymphocyte antigen 6 complex, locus E (LY6E) potently restricts infection by multiple CoVs, including SARS-CoV, SARS-CoV-2 and MERS-CoV. Mechanistic studies revealed that LY6E inhibits CoV entry into cells by interfering with spike protein-mediated membrane fusion. Importantly, mice lacking Ly6e in immune cells were highly susceptible to a murine CoV—mouse hepatitis virus. Exacerbated viral pathogenesis in Ly6e knockout mice was accompanied by loss of hepatic immune cells, higher splenic viral burden and reduction in global antiviral gene pathways. Accordingly, we found that constitutive Ly6e directly protects primary B cells from murine CoV infection. Our results show that LY6E is a critical antiviral immune effector that controls CoV infection and pathogenesis. These findings advance our understanding of immune-mediated control of CoV in vitro and in vivo—knowledge that could help inform strategies to combat infection by emerging CoVs.
Here, the authors identify lymphocyte antigen 6E (LY6E) as a coronavirus (CoV) restriction factor that prevents infection of B cells and dendritic cells. LY6E inhibits both human and mouse CoV entry into cells by interfering with viral spike protein-mediated membrane fusion. It facilitates an antiviral immune response that prevents liver disease and reduces death in the mouse model of MHV-A59 CoV infection. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 S.P., K.B.M., E.M., C.M.R., J.W.S., and V.T. designed the project. S.P., K.B.M., E.M., A.K., I.N.B., P.V., W.F., D.H., N.E., H.S., H.K-W., M.H., H.H.H., M.S., M.B.M., and G.Z. performed and analyzed in vitro experiments. K.B.M. performed and analyzed in vivo experiments with assistance from W.F. and N.W.H.. M. W-C. performed histological analysis. D.T. performed statistical analysis and analysis of MHV RNA-seq dataset. J.N.K. performed statistical analysis and analysis of hAEC RNA-seq dataset. R.D., S.Pö., E.S., and T.G. contributed to the design and implementation of the research. S.P., K.B.M., and J.W.S. wrote the manuscript, and all authors contributed to editing. equally contributing authors equal senior authorship Author contributions |
ISSN: | 2058-5276 2058-5276 |
DOI: | 10.1038/s41564-020-0769-y |